Back to resultsBioequivalency Study of Terbinafine Tablets Under Fasting Conditions
Primary Purpose
Onychomycosis
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Terbinafine
Sponsored by
About this trial
This is an interventional treatment trial for Onychomycosis
Eligibility Criteria
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to terbinafine or any comparable or similar product.
Sites / Locations
- Gateway Medical Research, Inc.
Outcomes
Primary Outcome Measures
Bioequivalence
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00602342
Brief Title
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
Official Title
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
March 2004 (undefined)
Primary Completion Date
April 2004 (Actual)
Study Completion Date
April 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Roxane Laboratories
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Onychomycosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Terbinafine
Primary Outcome Measure Information:
Title
Bioequivalence
Time Frame
Baseline, Two period, Twenty-one day washout
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion Criteria:
Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to terbinafine or any comparable or similar product.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Herrmann, MD
Organizational Affiliation
Cetero Research, San Antonio
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gateway Medical Research, Inc.
City
Saint Charles
State/Province
Missouri
ZIP/Postal Code
63301
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
We'll reach out to this number within 24 hrs